Skip to content

Virologic Response

PREZCOBIX® Offers the Durability of Darunavir1,2

Demonstrated durability over 192 weeks

ARTEMIS: DARUNAVIR COADMINISTERED
WITH RITONAVIR (SNAPSHOT ANALYSIS)*1,2

  • At Week 96, 78% of patients maintained an undetectable viral load1

  • At Week 192, 70% of patients maintained an undetectable viral load1

  • Virologic failure rates‡ were 12% for Once-Daily DRV/r and 15% for LPV/r in the 192-week snapshot analysis1

​

* These data—from a randomized, open-label, 192-week, Phase 3 study—show the proportion of TN adult patients achieving HIV-1 RNA <50 copies/mL over 192 weeks, which includes patients within Weeks 186 to 198, the last available measurement. 
† ITT-TLOVR: no snapshot analysis available at this time point. 
‡ Includes patients who discontinued prior to Week 192 for lack of efficacy, patients with ≥50 copies/mL in the 192-week window (186-198 weeks), and patients who had a change in their background regimen that was not permitted by the protocol. 

CI=confidence interval; DRV/r=darunavir coadministered with ritonavir; LPV/r=lopinavir/ritonavir; ITT-TLOVR=intent-to treat, time-to-loss of virologic response; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine; TN=treatment-naïve. 

References: 1. Data on file. Janssen Therapeutics, Division of Janssen Products, LP. 2. PREZCOBIX® [Prescribing Information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP.